Safety and efficacy of multiple cyclocoagulation of ciliary bodies by high-intensity focused ultrasound in patients with glaucoma
Session Details
Session Title: Presented Poster Session: Glaucoma
Venue: Poster Village: Pod 2
First Author: : A.De Gregorio ITALY
Co Author(s): : G. Stevan A. Bertoncello M. Montali S. Morselli
Abstract Details
Purpose:
To evaluate long-term efficacy and safety of ultrasound ciliary plasty (UCP) retreatments, with high intensity focused ultrasound (HIFU) in patients with uncontrolled glaucoma.
Setting:
Ophthalmic Unit, San Bassiano Hospital, Bassano del Grappa, Italy
Methods:
Prospective non-comparative case series study. Forty eyes of 40 patients older than 18 years affected by primary or secondary glaucoma with a baseline IOP > 21 mmHg under maximal tolerated medical therapy. A complete ophthalmic examination was performed before and after the procedure at 1, 4, 10 days and each month till 1 year.The HIFU treatment was repeated at 4 months if the intraocular pressure (IOP) was > 21 mmHg without major complications. Complete success was defined as a final IOP > 5 mmHg and ≤ 21 without hypotensive medications adjunction and without major or vision-threatening complications.
Results:
The mean preoperative IOP was 32.5 ± 9.9 mmHg. Four months after the first UCP the IOP reduction was 27.8%. Twenty-two eyes didn't achieve the complete success, a second treatment was performed in 20 eyes and 4 months after the IOP reduction was 20.3% from preoperative and 34.7% from baseline. Twelve retreated eyes didn't achieve the complete success, a third treatment was performed and 4 months after the IOP reduction was 33.6% and 52.6% from baseline. At 12 months 82.5% of treated eyes (1 to 3 UCPs) achieved a complete success with significant hypotensive medications reduction and no major complications.
Conclusions:
Our data demonstrated that multiple UCP treatments are safe and additional treatments increase the overall procedure efficacy with a possible step by step success achievement in most refractory glaucomatous eyes.
Financial Disclosure:
NONE
